Bandhan Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹11.4+0.27%
07 Sept 2026
Similar Funds
Side-by-side comparison of Bandhan Healthcare Fund Direct-Growth with similar funds — trailing returns, risk metrics, AUM and expense ratio.
| Period | This Fund | Category Avg | Category Rank |
|---|---|---|---|
| 1Y Return | — | 18.26% | — |
| 3Y Return | — | 22.79% | — |
| 5Y Return | — | 15.66% | — |
| 10Y Return | — | 15.35% | — |
Trailing annualised returns (%). Category rank: lower is better. Green = top third of category.
Funds in Equity: Sectoral-Pharma
Top funds by AUM in the Equity: Sectoral-Pharma category — see how Bandhan Healthcare Fund Direct-Growth compares on size and returns.
Funds Tracking BSE Healthcare Total Return Index
Top funds tracking the BSE Healthcare Total Return Index — sorted by AUM to show the largest options available.
Frequently Asked Questions
Which funds are similar to Bandhan Healthcare Fund Direct-Growth?
Funds similar to Bandhan Healthcare Fund Direct-Growth in the Equity: Sectoral-Pharma category include Nippon India Pharma Fund Direct-Growth, ICICI Prudential Healthcare Fund Direct-Growth, and SBI Healthcare Opportunities Fund Direct Plan-Growth. These funds follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the fund comparison tool on sharpely.
What is the rank of Bandhan Healthcare Fund Direct-Growth in its category?
The category rank of Bandhan Healthcare Fund Direct-Growth is shown in the Trailing Returns section above.
How does Bandhan Healthcare Fund Direct-Growth's expense ratio compare to similar funds?
Bandhan Healthcare Fund Direct-Growth has an expense ratio of 1.31%. The peers Nippon India Pharma Fund Direct-Growth has an expense ratio of 0.99% and ICICI Prudential Healthcare Fund Direct-Growth has 1.31%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the fund's performance justifies the additional cost.
How does Bandhan Healthcare Fund Direct-Growth's AUM compare to similar funds?
Bandhan Healthcare Fund Direct-Growth has an AUM of ₹319.48 crore. The peers Nippon India Pharma Fund Direct-Growth has an AUM of ₹9,279.11 crore and ICICI Prudential Healthcare Fund Direct-Growth has ₹6,802.61 crore. A large AUM can sometimes limit a fund's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for funds that invest outside large caps.
Which fund has the best 3-year returns in the Equity: Sectoral-Pharma?
The top performing fund in the Equity: Sectoral-Pharma category on a 3-year basis is UTI Healthcare Fund Direct-Growth with a CAGR of 24.47% as of 6 Sep 2026. Bandhan Healthcare Fund Direct-Growth has delivered - CAGR over the same period. You can view and compare the full category ranking on sharpely.
How does Bandhan Healthcare Fund Direct-Growth rank in risk-adjusted returns vs peers?
The Sharpe ratio of Bandhan Healthcare Fund Direct-Growth is shown in the Alpha, Beta & Sharpe section on the Performance tab.